Bluejay Investor Presentation Deck

Bluejay Diagnostics: Optimizing Turnaround Times to Improve Patient Outcomes $ DOC ●●● Novel Proprietary Platform ●● Symphony™ Product Lead Candidate: IL-6 Assay Market Opportunity Commercial Strategy $Capital Efficient Model bluejay DIAGNOSTICS Uses whole blood (no pre-processing) Results in ~20 minutes Completed initial clinical studies for measuring IL-6 in critical care settings Conducting additional studies to support planned FDA submission TM Symphony™ Product Pipeline addresses multi-billion-dollar market Near-patient testing (NPT) for monitoring of disease progression Sales model initially targets clinical sites and commercial partnerships Large, well-respected clinical sites are built-in commercial customers $6.8 M in cash as of March 31, 2023 The Symphony™ System and SymphonyTM Cartridge have not been cleared or approved by the U.S. FDA Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | June 2023 3

View entire presentation